Duvelisib for Critically Ill Patients With Coronavirus Disease 2019: An Investigator-Initiated, Randomized, Placebo-Controlled, Double-Blind Pilot Trial

BACKGROUND: Despite improvements in prevention and treatment, severe coronavirus disease 2019 (COVID-19) is associated with high mortality. Phosphoinositide 3-kinase (PI3K) pathways contribute to cytokine and cell-mediated lung inflammation. We conducted a randomized, placebo-controlled, double-blin...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldsmith, Scott R, Covut, Fahrettin, Fiala, Mark, Xiang, Zhifu, Iqbal, Zahid, Moore, Nathan, Bradtke, Elizabeth, Christen, Brandon, Rettig, Michael P, Christ, Stephanie, Gehrs, Leah, Street, Emily, Wallace, Nicholas, Ritchey, Julie, Gao, Feng, Pachter, Jonathan, Parikh, Bijal, Dubberke, Erik R, DiPersio, John F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10633784/
https://www.ncbi.nlm.nih.gov/pubmed/37953814
http://dx.doi.org/10.1093/ofid/ofad518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10633784/
https://www.ncbi.nlm.nih.gov/pubmed/37953814
http://dx.doi.org/10.1093/ofid/ofad518

Ejemplares similares